Evidence map›Paper›PMID 31934142›Full record

ArticleInternational journal of clinical and experimental pathology2019

The expressions and significance of B7-H3 and CTLA-4 in the clinical stages of non-small-cell lung cancer.

Zheng Liu, Meng-Miao Pei, Jun-Xia Liu, Fang Shi, Ye Zhang, Dong-Fang Zhao, Jian-Ming Li, Feng-Rui Guo, Jing-Jing Yan, Jia-Qi Liu and 1 more

Abstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zheng LiuDepartment of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University Langfang, Hebei, China.
Meng-Miao PeiDepartment of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University Langfang, Hebei, China.
Jun-Xia LiuDepartment of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University Langfang, Hebei, China.
Fang ShiDepartment of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University Langfang, Hebei, China.
Ye ZhangDepartment of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University Langfang, Hebei, China.
Dong-Fang ZhaoDepartment of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University Langfang, Hebei, China.
Jian-Ming LiDepartment of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University Langfang, Hebei, China.
Feng-Rui GuoDepartment of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University Langfang, Hebei, China.
Jing-Jing YanDepartment of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University Langfang, Hebei, China.
Jia-Qi LiuFaculty of Science-Medical Science Major, University of Western Ontario Canada.
Yin-Peng LiDepartment of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University Langfang, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to analyze the expressions and significance of B7-H3 and CTLA-4 in the clinical stages of non-small-cell lung cancer (NSCLC). Seventy patients with NSCLC who underwent surgical resection or biopsy between January 2016 and February 2018 were enrolled. Among them, 30 were cases of paracancerous tissues and were assigned to the control group (CON). These cases were analyzed using immunochemical methods. Of the 70 cases, 48 were of adenocarcinoma, 19 were of squamous cell carcinoma, and 3 were of adenosquamous carcinoma. The expression rates of B7-H3 and CTLA-4 in the observation group (OBS) were 64.2% and 57.1% respectively, and those in the CON group were 6.7% and 0%, respectively (χ

Indexed as

B7-H3clinical stagesCTLA-4histopathologyNSCLC

Identifiers

PMID31934142
PMCPMC6949705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.